Home

Eli Lilly (LLY)

767.07
+16.29 (2.17%)
NYSE · Last Trade: Jun 4th, 4:09 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close750.78
Open756.39
Bid766.87
Ask767.27
Day's Range756.00 - 772.62
52 Week Range677.09 - 972.53
Volume2,353,857
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.000 (0.78%)
1 Month Average Volume5,091,992

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Pointbenzinga.com
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 4, 2025
The 9 Best Stocks to Buy Now in June (2025)fool.com
Via The Motley Fool · June 4, 2025
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Dealbenzinga.com
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Via Benzinga · June 4, 2025
Better Dividend ETF to Buy Now: Schwab U.S. Dividend Equity ETF or Vanguard Dividend Appreciation ETF?fool.com
Dive deep into two popular dividend ETFs to determine which is right for your portfolio.
Via The Motley Fool · June 4, 2025
1 Underrated Reason to Buy This Market-Beating Stockfool.com
Via The Motley Fool · June 4, 2025
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027fool.com
Via The Motley Fool · June 4, 2025
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europeinvestors.com
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Via Investor's Business Daily · June 3, 2025
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In Junebenzinga.com
Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Via Benzinga · June 2, 2025
Could Viking Therapeutics Become the Next Eli Lilly?fool.com
Via The Motley Fool · June 2, 2025
Eli Lilly Rises 1.5% After Key Trading Signalbenzinga.com
A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Via Benzinga · June 2, 2025
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Via PR Leap · June 2, 2025
Veru's Enobosarm Shows Muscle In Wegovy Combo Trialbenzinga.com
Via Benzinga · May 28, 2025
P/E Ratio Insights for Eli Lillybenzinga.com
Via Benzinga · May 27, 2025
Top S&P500 movers in Friday's sessionchartmill.com
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 30, 2025
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failureinvestors.com
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via Investor's Business Daily · May 30, 2025
2 Top Stocks to Buy With Less Than $100fool.com
Via The Motley Fool · May 30, 2025
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failureinvestors.com
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Via Investor's Business Daily · May 30, 2025
3 American Growth Giants to Invest in for the Long Haulfool.com
Via The Motley Fool · May 30, 2025
2 Beaten-Down Stocks to Buy on the Dipfool.com
Via The Motley Fool · May 30, 2025
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF.fool.com
Via The Motley Fool · May 30, 2025
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lillyinvestors.com
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.
Via MarketBeat · May 29, 2025
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?fool.com
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Via The Motley Fool · May 28, 2025
Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?benzinga.com
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.
Via Benzinga · May 27, 2025